SXI Life Sciences
6.905,90
PKT
+48,39
PKT
+0,71
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
21.04.05 | Roche Outperform | Goldman Sachs | |
21.04.05 | Novartis Buy | Merrill Lynch | |
21.04.05 | Roche Sector Outperform | Vontobel | |
21.04.05 | Novartis Akkumulieren | Independent Research | |
21.04.05 | Novartis Neutral | Sarasin Research | |
22.04.05 | Novartis Kaufen | Helaba Trust | |
20.04.05 | Roche Buy | Sarasin Research | |
20.04.05 | Roche Outperform | Goldman Sachs | |
20.04.05 | Roche Overweight | JP Morgan | |
20.04.05 | Roche Equal weight | Lehman Brothers | |
19.04.05 | BB Biotech Kaufen | Hamburger Sparkasse | |
19.04.05 | Novartis Buy | Merrill Lynch | |
19.04.05 | Roche Halten | Helaba Trust | |
21.04.05 | Novartis Underperform | Credit Suisse First Boston | |
19.04.05 | Roche Akkumulieren | Independent Research | |
19.04.05 | Roche Buy | Sarasin Research | |
18.04.05 | Novartis Outperform | Goldman Sachs | |
19.04.05 | Roche Equal weight | Lehman Brothers | |
19.04.05 | Novartis Neutral | JP Morgan | |
19.04.05 | Roche Overweight | JP Morgan | |
15.04.05 | Novartis Kaufen | Helaba Trust | |
15.04.05 | Roche In-Line | Goldman Sachs | |
18.04.05 | Novartis Neutral | Sarasin Research | |
15.04.05 | Roche In-Line | Goldman Sachs | |
18.04.05 | Novartis Neutral | HypoVereinsbank | |
18.04.05 | Roche Buy | Sarasin Research | |
18.04.05 | Roche Buy | Helvea | |
18.04.05 | Roche Outperform | HypoVereinsbank | |
14.04.05 | Novartis Reduce | UBS | |
14.04.05 | Novartis Reduce | UBS | |
14.04.05 | Roche Halten | Helaba Trust | |
15.04.05 | Novartis Underperform | Credit Suisse First Boston | |
15.04.05 | Roche Buy | SES Research | |
13.04.05 | Lonza Reduce | Sarasin Research | |
13.04.05 | Novartis Neutral | Sarasin Research | |
11.04.05 | Lonza Overweight | JP Morgan | |
08.04.05 | Novartis Accumulate | Helvea | |
07.04.05 | Lonza Reduce | Sarasin Research | |
06.04.05 | Roche Buy | Helvea | |
29.03.05 | Siegfried Sector Perform | Vontobel |